Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction
- PMID: 22042215
- DOI: 10.1097/ADM.0b013e3182312983
Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction
Abstract
Objectives: Opioid addiction affects over 2 million patients in the United States. The advent of buprenorphine and the passage of the Drug Addiction Treatment Act in 2000 have revolutionized the opioid treatment delivery system by granting physicians the ability to administer office-based opioid treatment (OBOT), thereby giving patients greater access to treatment. The purpose of this consensus panel was to synthesize the most current evidence on the use of buprenorphine in the office-based setting and to make recommendations that will enable and allow additional physicians to begin to treat opioid-addicted individuals.
Methods: Literature published from 2000 to 2009 was searched using the PubMed search engine and yielded over 375 articles published in peer-reviewed journals, including some that were published guidelines. These articles were submitted to a consensus panel composed of researchers, educators, and clinicians who are leaders in the field of addiction medicine with specific expertise in the use of OBOT. The panel discussed results and agreed upon consensus recommendations for several facets of OBOT.
Results: : On the basis of the literature review and consensus discussions, the panel developed a series of findings, conclusions, and recommendations regarding the use of buprenorphine in office-based treatment of opioid addiction.
Conclusions: Therapeutic outcomes for patients who self-select office-based treatment with buprenorphine are essentially comparable to those seen in patients treated with methadone programs. There are few absolute contraindications to the use of buprenorphine, although the experience and skill levels of treating physicians can vary considerably, as can access to the resources needed to treat comorbid medical or psychiatric conditions--all of which affect outcomes. It is important to conduct a targeted assessment of every patient to confirm that the provider has resources available to meet the patient's needs. Patients should be assessed for a broad array of biopsychosocial needs in addition to opioid use and addiction, and should be treated, referred, or both for help in meeting all their care needs, including medical care, psychiatric care, and social assistance. Current literature demonstrates promising efficacy of buprenorphine, though further research will continue to demonstrate its effectiveness for special populations, such as adolescents, pregnant women, and other vulnerable populations. Since the time of this review, several new studies have provided new data to continue to improve our understanding of the safety and efficacy of buprenorphine for special patient populations.
Similar articles
-
Consensus statement on office-based treatment of opioid dependence using buprenorphine.J Subst Abuse Treat. 2004 Sep;27(2):153-9. doi: 10.1016/j.jsat.2004.06.005. J Subst Abuse Treat. 2004. PMID: 15450648 Review.
-
Buprenorphine for office-based treatment of patients with opioid addiction.J Am Osteopath Assoc. 2005 Jun;105(6 Suppl 3):S8-13. J Am Osteopath Assoc. 2005. PMID: 16118361 Review.
-
Primary care patient characteristics associated with completion of 6-month buprenorphine treatment.Addict Behav. 2013 Nov;38(11):2724-8. doi: 10.1016/j.addbeh.2013.07.007. Epub 2013 Jul 25. Addict Behav. 2013. PMID: 23934003
-
Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.N Engl J Med. 2003 Sep 4;349(10):949-58. doi: 10.1056/NEJMoa022164. N Engl J Med. 2003. PMID: 12954743 Clinical Trial.
-
Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23. Pain Pract. 2008. PMID: 18503626
Cited by
-
Patient and Clinician Experiences with the Implementation of Telemedicine and Related Adaptations in Office-Based Buprenorphine Treatment During the COVID-19 Pandemic: A Qualitative Study.Res Sq [Preprint]. 2024 Apr 22:rs.3.rs-4272282. doi: 10.21203/rs.3.rs-4272282/v1. Res Sq. 2024. PMID: 38746460 Free PMC article. Preprint.
-
"They make it too hard and too many hoops to jump": system and organizational barriers to drug treatment during epidemic rates of opioid overdose.Harm Reduct J. 2024 Feb 27;21(1):52. doi: 10.1186/s12954-024-00964-5. Harm Reduct J. 2024. PMID: 38413972 Free PMC article.
-
Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing: A Prespecified Secondary Analysis of the HCS Randomized Clinical Trial.JAMA Netw Open. 2024 Feb 5;7(2):e240132. doi: 10.1001/jamanetworkopen.2024.0132. JAMA Netw Open. 2024. PMID: 38386322 Free PMC article.
-
Opening the "black box": Four common implementation strategies for expanding the use of medications for opioid use disorder in primary care.Implement Res Pract. 2021 May 19;2:26334895211005809. doi: 10.1177/26334895211005809. eCollection 2021 Jan-Dec. Implement Res Pract. 2021. PMID: 37090014 Free PMC article.
-
Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines.J Hosp Med. 2022 Sep;17(9):679-692. doi: 10.1002/jhm.12908. Epub 2022 Jul 26. J Hosp Med. 2022. PMID: 35880821 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical